Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Novartis
Kivu Bioscience Inc.
National Cancer Institute (NCI)
Travera Inc
Bayer
Alliance for Clinical Trials in Oncology
Actuate Therapeutics Inc.
Eastern Cooperative Oncology Group